Pancholy Samir B
Mercy Hospital and Community Medical Center, Scranton, Pennsylvania, USA.
Am J Cardiol. 2009 Oct 15;104(8):1083-5. doi: 10.1016/j.amjcard.2009.05.057. Epub 2009 Aug 25.
Radial artery occlusion (RAO) is an infrequent, asymptomatic, complication of transradial catheterization and probably 1 of the few. Intravenous heparin and patent hemostasis lower its incidence. A possible local effect of intra-arterially administered heparin during transradial procedures has not been evaluated. We studied 500 consecutive patients randomized to an intravenous group (n = 250), receiving 50 U/kg of unfractionated heparin (maximal dose 5,000 U) intravenously, and an intra-arterial group (n = 250) receiving the same dose intra-arterially. All patients received a vasodilator "cocktail" intra-arterially and underwent cardiac catheterization using a 5F introducer sheath and catheters. The activated clotting time was measured at the end of the procedure. All patients received hemostasis with a radial compression device (TR Band), applied after sheath removal, for 2 hours. A plethysmographic evaluation for RAO was performed at 24 hours and 30 days after the procedure. Early RAO occurred in 5.6% (n = 14) of the intravenous group and 6% (n = 15) of the intra-arterial group. The difference was not statistically significant (chi-square = 0.037, p >0.8). Chronic RAO occurred in 3.2%, (n = 8) of the intravenous group compared to 4% (n = 10) of the intra-arterial group. The difference was not statistically significant (chi-square = 0.231, p >0.6). The activated clotting time was 211 +/- 16 seconds in the intravenous group and 213 +/- 17 seconds in the intra-arterial group, a statistically insignificant difference (t = -1.095, p >0.2). In conclusion, intra-arterial and intravenous heparin administration provide comparable efficacy in preventing RAO, favoring a probable systemically mediated mechanism of action, rather than a local effect.
桡动脉闭塞(RAO)是经桡动脉导管插入术一种罕见的、无症状的并发症,可能是少数此类并发症之一。静脉注射肝素和有效的止血措施可降低其发生率。经桡动脉操作期间动脉内注射肝素可能产生的局部效应尚未得到评估。我们研究了500例连续患者,随机分为静脉注射组(n = 250),静脉注射50 U/kg的普通肝素(最大剂量5000 U),以及动脉内注射组(n = 250),动脉内注射相同剂量的肝素。所有患者均动脉内给予血管扩张剂“鸡尾酒”,并使用5F导入鞘管和导管进行心脏导管插入术。在操作结束时测量活化凝血时间。所有患者在拔除鞘管后使用桡动脉压迫装置(TR Band)进行止血2小时。在术后24小时和30天对RAO进行体积描记评估。静脉注射组早期RAO发生率为5.6%(n = 14),动脉内注射组为6%(n = 15)。差异无统计学意义(卡方 = 0.037,p >0.8)。静脉注射组慢性RAO发生率为3.2%(n = 8),动脉内注射组为4%(n = 10)。差异无统计学意义(卡方 = 0.231,p >0.6)。静脉注射组活化凝血时间为211±16秒,动脉内注射组为213±17秒,差异无统计学意义(t = -1.095,p >0.2)。总之,动脉内和静脉内给予肝素在预防RAO方面具有相当的疗效,这支持了可能是全身介导的作用机制,而非局部效应。